← Back to Search

Other

HSK3486 for General Anesthesia

Phase 3
Waitlist Available
Research Sponsored by Haisco-USA Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 minutes from end of drug administration
Awards & highlights

Study Summary

This trialshows HSK3486 is as effective as propofol for inducing general anesthesia in adults undergoing elective surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 minutes from end of drug administration
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 minutes from end of drug administration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Success rate of general anesthesia induction
Secondary outcome measures
Proportion of subjects with any injection-site pain on Numeric Rating Scale
Proportion of subjects with successful induction who maintain the desired depth of anesthesia for general elective surgery, AND without significant cardiac and respiratory depression

Side effects data

From 2022 Phase 3 trial • 255 Patients • NCT04711837
28%
Hypotension
27%
Nausea
19%
Procedural Pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
HSK3486
Propofol

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: HSK3486Experimental Treatment1 Intervention
HSK3486 for general anesthesia induction
Group II: PropofolActive Control1 Intervention
Propofol for general anesthesia induction
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HSK3486
2019
Completed Phase 3
~1630

Find a Location

Who is running the clinical trial?

Haisco-USA Pharmaceuticals, Inc.Lead Sponsor
3 Previous Clinical Trials
696 Total Patients Enrolled
2 Trials studying General Anesthesia
441 Patients Enrolled for General Anesthesia

Media Library

HSK3486 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05478174 — Phase 3
General Anesthesia Research Study Groups: HSK3486, Propofol
General Anesthesia Clinical Trial 2023: HSK3486 Highlights & Side Effects. Trial Name: NCT05478174 — Phase 3
HSK3486 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05478174 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there short-term or long-term dangers to taking HSK3486?

"Although this is only a phase 3 trial, there is some evidence of efficacy and HSK3486's safety has been corroborated multiple times. Therefore, it receives a score of 3."

Answered by AI

Are there any restrictions on who is allowed to enroll in this research project?

"Eligible participants for this study must be able to undergo general anesthesia and be between 18-99 years old. There is a total of 399 slots for this clinical trial."

Answered by AI

Is this clinical trial restricted to people under the age of 20?

"The age group that this study is targeting is individuals who are over 18 and under 99 years old."

Answered by AI

Who else is applying?

What state do they live in?
Tennessee
What site did they apply to?
Arizona Research Center
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2
~150 spots leftby Apr 2025